PATHOQUEST
23.1.2020 14:02:09 CET | Business Wire | Press release
PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility receive such a GLP certificate from the ANSM for advanced, Next Generation Sequencing viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells ”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005345/en/
Violaine Melen, PathoQuest’s Chief of Quality Assurance and Regulatory Affairs, stated “we are really proud of the achievement of this key regulatory milestone. Receiving this GLP certificate is the confirmation of the quality of our entire process, from receipt of a biological sample to report generation, inclusive of bioinformatics analysis and data archiving. Our processes have been validated in accordance with highly recognized validation methods and computer systems guidelines such as ICHQ2(R1), IEC 62304, 21 CRF part 11, OECD annex 17.”
Next generation sequencing-based technology for biologics testing is intended to supplement or replace traditional in-vivo or in-vitro testing methods in order to support more rapid and robust decision-making as a part of the QC process. Jean-François Brepson, PathoQuest’s CEO, commented “Thanks to efficient teamwork, PathoQuest is now able to offer GLP-certified viral safety testing based on our proprietary NGS approach. This certification provides the company with a significant new market opportunity in addition to the current testing we perform in a R&D environment. Our innovative QC process is particularly adapted to biotech and biopharma companies developing Advanced Therapy Medicinal Products (ATMPs), vaccines and other biologicals .”
About PathoQuest
PathoQuest offers biopharmaceutical companies a game changing Genomic approach to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and recombinant. It allows to reduce time to market of innovative treatments.
PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with a proprietary sample preparation processes completed by a proprietary pathogen genome sequence databases and automated analysis pipeline.
PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR)
For more information about PathoQuest, visit www.pathoquest.com or contact us at welcome@pathoquest.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove
Global New Material International Wins Technology Innovation Best Practice Award at Sino-European ESG Conference6.7.2026 05:59:00 CEST | Press release
Global New Material International Holdings Ltd. has received the Technology Innovation Best Practice Award at the Third Sino-European Corporate ESG Best Practice Conference recently in Mainz, Germany, in recognition of its efforts to advance sustainable development through material innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260705533555/en/ Thorsten Giehler (L), Director of the Economic, Social Development and Employment Division of The German Society for International Cooperation (GIZ), delivered the award to Zhou Fangchao, Executive Director and Vice President of Global New Material International. The annual conference, initiated by the Chinese Consulate General in Frankfurt and jointly organized with Chinese and European partners, recognizes corporate best practices in environmental, social and governance (ESG) performance. This year's event brought together government officials, business leaders and exper
Access Advance Welcomes Samsung and Sharp to the VVC Advance Patent Pool6.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced significant additions to the VVC Advance Patent Pool, including Samsung Electronics and Sharp Corporation joining as both Licensors and Licensees. The additions strengthen Access Advance's position in VVC licensing, bringing two of the world's largest video codec patent holders into the program on both sides of the license. "The growth we are seeing in VVC Advance reflects the broad range of industries and companies that are moving toward VVC as the next standard for video delivery," said Peter Moller, CEO of Access Advance. "Samsung and Sharp joining as both Licensors and Licensees is significant, but so is the participation of leading smartphone brands and the range of consumer electronics and technology companies now executing licenses. We are building a program that reflects where the video market is actually heading." The following companies have joined the VVC Advance Patent Pool as Licensees since the beginning of 2026: American Future Technolo
Kioxia and Sandisk Begin Production of 10th-Generation 3D Flash Memory Products atKitakami Plant Fab23.7.2026 12:19:00 CEST | Press release
Companies Showcase Ongoing Buildout of Manufacturing Infrastructure at K2 to Address Growing Demand for NAND Flash Kioxia Corporation, a subsidiary of Kioxia Holdings Corporation (TOKYO: 285A) and Sandisk Corporation (Nasdaq: SNDK) today announced the start of production for their 10th-generation 3D Flash memory technology at Fab2 (K2) at the Kitakami Plant in Iwate Prefecture in Japan. The milestone comes as the companies continue to drive meaningful, multi-year bit growth to address the strong demand for their innovative flash memory technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702296115/en/ Unveiling ceremony for the K2 facility In conjunction with the start of production, the companies held an unveiling ceremony for the K2 facility. Opening in September 2025, the facility has produced the companies’ 8th-generation 3D flash memory products and will begin to scale production with the introduction of their
VeriSilicon Introduces CPP2000 Camera Post-Processing IP for Embodied Robotics and Mobile Vision Applications3.7.2026 12:02:00 CEST | Press release
Enhancing image quality and visual perception for moving-camera systems VeriSilicon (688521.SH) today announced its high-performance CPP2000 Camera Post-Processing (CPP) IP, expanding the company’s Image Signal Processing (ISP) solutions with advanced post-processing capabilities. By improving image quality and visual perception in mobile imaging scenarios, CPP2000 enables more reliable vision performance in robotics, drones, and other mobile vision applications. CPP2000 integrates multiple image processing technologies and can further optimize YUV images output from image signal processors. The IP supports image and video processing at up to 8K resolution and offers multiple hardware configuration options to meet diverse requirements in Power, Performance, Area (PPA), and latency across different applications. CPP2000 leverages the combined operation of multiple image processing technologies, including motion-compensated temporal filtering, advanced spatial noise reduction, chroma adj
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom